Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group.
Asia-Pacific ACS Medical Management Working Group; Huo Y, Thompson P, Buddhari W, Ge J, Harding S, Ramanathan L, Reyes E, Santoso A, Tam LW, Vijayaraghavan G, Yeh HI. Asia-Pacific ACS Medical Management Working Group, et al. Among authors: huo y. Int J Cardiol. 2015 Mar 15;183:63-75. doi: 10.1016/j.ijcard.2014.11.195. Epub 2014 Nov 28. Int J Cardiol. 2015. PMID: 25662044 Review.
Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registry.
Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, Gai LY, Ge JB, Wang WM, Du ZM, Huo Y, Wang LF, Gao W, Chen JY, He B, Jia GL, Yang ZJ, Cao KJ, Li WM, Shen WF, Wan Z, Huang DJ, Zhu GY; CCSR Investigators. Gao RL, et al. Among authors: huo y. Int J Cardiol. 2008 Apr 25;125(3):339-46. doi: 10.1016/j.ijcard.2007.02.031. Epub 2007 Apr 16. Int J Cardiol. 2008. PMID: 17434617
Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial.
Zhang Y, Chen F, Muramatsu T, Xu B, Li Z, Ge J, He Q, Yang Z, Li S, Wang L, Wang H, He B, Li K, Qi G, Li T, Zeng H, Peng J, Jiang T, Zeng Q, Zhu J, Fu G, Bourantas CV, Serruys PW, Huo Y. Zhang Y, et al. Among authors: huo y. Chin Med J (Engl). 2014;127(11):2153-8. Chin Med J (Engl). 2014. PMID: 24890170 Clinical Trial.
Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia).
Huo Y, Lee SW, Sawhney JP, Kim HS, Krittayaphong R, Nhan VT, Alonso-Garcia A, Han YL, Ge J, Chin CT, Ong TK, Jan S, Itoh Y, Vega AM, Pocock S. Huo Y, et al. Clin Cardiol. 2015 Sep;38(9):511-9. doi: 10.1002/clc.22431. Epub 2015 Jul 24. Clin Cardiol. 2015. PMID: 26206158 Free PMC article.
[Efficacy comparison between 5 mg perindopril arginine salt and 4 mg perindopril tert-butylamine salt for patients with mild to moderate essential hypertension].
Qi L, Zhao S, Li H, Guo Y, Xu G, Ge J, Wu S, Miao P, Jin Y, Yang J, Wu X, Ma C, Xu D, Luo J, Wang B, Li G, Wang F, Shen F, Shi H, Huo Y. Qi L, et al. Among authors: huo y. Zhonghua Xin Xue Guan Bing Za Zhi. 2015 Oct;43(10):863-7. Zhonghua Xin Xue Guan Bing Za Zhi. 2015. PMID: 26652987 Clinical Trial. Chinese.
Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial.
Liu Y, Chen JY, Huo Y, Ge JB, Xian Y, Duan CY, Chen SQ, Jiang W, Chen PY, Tan N; RESCIND group. Liu Y, et al. Among authors: huo y. Am Heart J. 2016 Feb;172:88-95. doi: 10.1016/j.ahj.2015.10.007. Epub 2015 Oct 20. Am Heart J. 2016. PMID: 26856220 Clinical Trial.
3,507 results